Abstract
In this paper we present a new HPLC method for the determination of novobiocin in human serum. The assay uses mitomycin C as an internal standard, protein precipitation with acetonitrile, an ODS reversed-phase column with an isocratic mobile phase of acetonitrile—0.01 M phosphoric acid (80:20, v/v), and UV detection at 340 nm. The assay has a lower limit of quantitation of 1 μg/ml and is linear over the range of 1–1000 μg/ml. The assay is ideally suited for use in clinical trials as it requires minimal amounts of serum, is highly sensitive and reproducible, is performed with minimal sample preparation, and involves a short run time. It should prove important in evaluating the potential of novobiocin as a means to modulate resistance to antineoplastic chemotherapy and in therapeutic drug monitoring of the growing number of patients receiving novobiocin to control methicillin-resistant Staphylococcus aureus infections.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Chromatography B: Biomedical Sciences and Applications
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
